US Stock MarketDetailed Quotes
CALT Calliditas Therapeutics
- 40.000
- 0.0000.00%
Trading Sep 20 16:00 ET
1.08BMarket Cap-24660P/E (TTM)
0.000High0.000Low0Volume0.000Open40.000Pre Close0.00Turnover0.00%Turnover RatioLossP/E (Static)27.02MShares43.00052wk High111.73P/B13.54MFloat Cap16.00052wk Low--Dividend TTM338.45KShs Float43.000Historical High--Div YieldTTM0.00%Amplitude10.820Historical Low--Avg Price1Lot Size
About Calliditas Therapeutics Company
Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, initially focusing on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.
Company Profile
SymbolCALT
Company NameCalliditas Therapeutics
Issue Price19.50
CEOMs. Renee Aguiar-Lucander
MarketNASDAQ
Employees195
Securities TypeDR
ADS Ratio1.0 : 2.0
Fiscal Year Ends12-31
Company Executives
- Name
- Position
- Salary
- Renee Aguiar-Lucander
- Chief Executive Officer
- --
- Dr. Richard Philipson, M.D.
- Chief Medical Officer
- --
- Fredrik Johansson
- Chief Financial Officer
- --
- Dr. Frank Bringstrup, M.D.
- Vice President, Regulatory Affairs
- --
- Monika Maria Tornsen
- President, North America
- --
- Elmar Schnee
- Chairman of the Board
- --
- Hilde Furberg
- Independent Director
- --
- Diane L. Parks, M.B.A.
- Independent Director
- --
- Henrik Stenqvist
- Independent Director
- --
- Frederick W. Driscoll
- Independent Director
- --
- Dr. Elisabeth Bjork, M.D.,PhD
- Independent Director
- --
- Brian Gorman
- Group General Counsel
- --
- Lars Stubberud
- Head of Technical Operations
- --
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data